By Karen E. Roman
Octave Bioscience, Inc., a company offering treatment for multiple sclerosis and other neurodegenerative diseases, said it will conduct a real-world study with its sponsor Biogen (Nasdaq: BIIB) evaluating 150 patients using the Octave Precision Care Solution.
Octave’s Solution includes the first and only multivariate blood test to measure MS Disease Activity and a digital clinical program that actively and passively tracks patients day-to-day and connects them to expert MS nurse practitioners, the company said.
“The initiation of this study marks an important milestone as we work with one of the leading companies in MS and neuroscience to obtain deeper insights about patients and their treatments, and ultimately enable improved care for these patients,” said William Hagstrom, Octave’s Founder and CEO.
The company said that the study will take place at the Rocky Mountain MS Clinic, Oklahoma Medical Research Foundation’s MS Center of Excellence, and Orlando Health MS Comprehensive Care Center.
Contact:
Editor@Executives-edge.com
